(Q38542034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

review article

1 reference

title

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

M Christina Cox

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Gabriella Palmieri

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

3

Angela Santoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

1 reference

1 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

Journal of Leukocyte Biology

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

87-96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26136506%20AND%20SRC:MED&resulttype=core&format=json

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Classification of current anticancer immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The immune system and response to HER2-targeted treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Anti-CD20 antibody therapy for B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Translational medicine in action: anti-CD20 therapy in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Accelerated therapeutic progress in diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The role of complement in mAb-based therapies of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Fcgamma receptors: old friends and new family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Properties of mouse and human IgG receptors and their contribution to disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The future of anti-CD20 monoclonal antibodies: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Novel CD20 monoclonal antibodies for lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Three major uncertainties in the antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Clinical utility of natural killer cells in cancer therapy and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Recognition of tumors by the innate immune system and natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Human natural killer cells: origin, receptors, function, and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Developmental pathways that generate natural-killer-cell diversity in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cell development, homeostasis and function: parallels with CD8⁺ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Location and cellular stages of natural killer cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cells: walking three paths down memory lane

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cell distribution and trafficking in human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Intravital Imaging Reveals Distinct Dynamics for Natural Killer and CD8+ T Cells during Tumor Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Up on the tightrope: natural killer cell activation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Controlling natural killer cell responses: integration of signals for activation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cell biology: an update and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Killer immunoglobulin-like receptors and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Balancing natural killer cell activation through paired receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Promiscuity and the single receptor: NKG2D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NKG2D ligands in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The NKG2D receptor: immunobiology and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

New prospects on the NKG2D/NKG2DL system for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Regulation of ligands for the NKG2D activating receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Advances in NKG2D ligand recognition and responses by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Molecular Bases for the Regulation of NKG2D Ligands in Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Interferons, immunity and cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural-killer cells and dendritic cells: "l'union fait la force".

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cells: the secret weapon in dendritic cell vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Combination immune therapies to enhance anti-tumor responses by NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Unifying concepts of MHC-dependent natural killer cell education

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Tuning the threshold of natural killer cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cell self tolerance, responsiveness and missing self recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Continuous engagement of a self-specific activation receptor induces NK cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Regulation of fc receptor endocytic trafficking by ubiquitination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

New antibody approaches to lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Novel immunotherapies for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Bispecific antibody platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Targeting natural killer cells and natural killer T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cell-based immunotherapy for malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Targeting CD137 enhances the efficacy of cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

NK cell MHC class I specific receptors (KIR): from biology to clinical intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Novel therapeutic agents for B-cell lymphoma: developing rational combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Infusions of allogeneic natural killer cells as cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Immune modulation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Harnessing the immune system for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.5VMR0415-141R